You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

The Role of Trastuzumab in Adjuvant and Neoadjuvant Therapy in Women with HER2/neu-overexpressing Breast Cancer

Version: 2 ID: 1-24 Version 2 mai 2006
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Authors:
Breast Cancer Disease Site Group

Research Question(s)

In women with HER2/neu-overexpressing breast cancer:

  1. Compared with adjuvant or neoadjuvant chemotherapy alone, does trastuzumab in combination with chemotherapy improve clinically meaningful outcomes (overall response rate, time-to-disease-progression, overall survival, toxicity, or quality of life)?
  2. Compared with placebo or observation, does single-agent trastuzumab adjuvant or neoadjuvant therapy improve clinically meaningful outcomes?
  3. What is the best way to identify women who will benefit from adjuvant or neoadjuvant trastuzumab therapy?
  4. What are the adverse events associated with adjuvant or neoadjuvant trastuzumab therapy?
  5. What are the optimal dose, schedule, and duration for adjuvant trastuzumab therapy?
pdf download Full Report (PDF) (1005.06 Ko)